WE PRIORITIZE TIMELY RESOLUTION OF YOUR QUERIES WITH PROFESSIONAL COMMITMENT
Critical care studies are fraught with challenges including volatility of patient health, the need for rapid interdepartmental communication at sites, elevated mortality rates and consent concerns. Our extensive experience in critical care means we are adept at overcoming common challenges to quickly move your program forward.
We offer nuanced approaches that address common issues such as:
Informed consent — We have proven processes to facilitate emergency consent using legally authorized representatives (LARs) per country-specific regulatory guidelines, if a patient is unable to consent.
Management of inter-departmental relationships — Not only do we select the right sites, but we also work to ensure that all involved departments (emergency rooms, intensive care units, radiology units, etc.) have a well-scripted, trial-specific plan to smoothly work together and overcome obstacles.
Complex local regulations — Our understanding of the expectations of local institutional review boards or independent ethics committees helps pave the way to submission documents that result in swift approval.
Investigator engagement — We have developed many regional/country-specific best practices to actively engage investigators as early as possible in the process and maintain site involvement and enthusiasm.
Key Indications:
Post-transplant complications
Hemorrhage
Sepsis
Ventilator-associated pneumonia
Acute respiratory distress syndrome
Burns
Brain injury
In Settings Including:
Emergency rooms
Intensive care units (ICU)
Operating rooms
Radiology units
Blood banks
GLOBAL PROFESSIONALS WITH IN-HOSPITAL AND ICU EXPERIENCE
We have a team of professionals with critical experience, including those who have worked as nurses and physicians in an ICU setting. Not only do they understand how to conduct quality clinical trials in a high-stakes critical care setting, they will also help you anticipate the expectations of local institutional review boards and independent ethics committees and plan for informed consent challenges with strategies that include utilization of LARs.In addition, we maintain relationships with key opinion leaders and give you access to a global network of seasoned critical care investigators and hundreds of qualified sites in all regions.
INVESTIGATIVE NETWORK FOR CONTAMINATED DISEASE STUDIES
It is essential to have access to a global investigator database that comprises experts in infectious diseases. By using KLCRO, you can get in touch with experts in infectious diseases in:
Bacterial, fungal and parasitic diseases
Chronic hepatitis B and C
COVID-19
HIV
Influenza
Pediatric indications
Research and Drug Development in HIV
KLCRO is committed to advance the fight against HIV/AIDS via ground-breaking scientific innovation and collaboration as a leader in HIV medication development and research. We are at the forefront of efforts to produce safe, efficient, and easily accessible medicines for HIV infection because of our decades of experience and unwavering commitment to addressing the problems faced by this worldwide pandemic. Our extensive experience includes trials addressing:
Opportunistic infections
Co-infections
Highly active antiretroviral therapies (HAART)
Global COVID-19 Treatment Studies
Sites
Patients and Subjects
COVID-19 Experience:
You want a skilled infectious disease CRO on hand in case of a pandemic. Drug makers looked for partners with extensive and pertinent expertise, like KLCRO, to steer therapies from clinical trials to post-approval as COVID-19 spread over the world. We swiftly acquired significant, specialized, and practical experience in managing international COVID-19 programs with sponsors, and we are equipped to handle any pandemic in the future.
The ability to quickly develop solutions through teamwork, access to end-to-end solutions, and a solid foundation of infectious disease experience were the cornerstones of the COVID-19 programs’ success.
Benefit from KLCRO’s breadth of experience and skills to strategically position your upcoming coronavirus clinical studies, which include: